Coloplast plans to acquire Iceland-based biotech company Kerecis for up to $1.3bn to improve its biologics offerings in the rapidly growing advanced would care market, especially in the US.
The companies expect the deal to close by the end of Coloplasts’ fiscal year in September
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?